

# TABLE OF CONTENTS

May 24, 2010

No. 2189

## BUSINESS

- 1 Astellas to Acquire OSI Pharmaceuticals
  - Enhancing Business Platform in Top-Priority Oncology Field
  - Offer Period Extended to June 2
- 3 Joji Nakayama to Be Appointed President of Daiichi Sankyo
- 4 Takeda: Sales Down 4.7% Due to Patent Expiration for Lansoprazole in the US
  - Revised Mid-Term Management Plan Aims at Smaller Sales, Profits
  - To Reduce Headcount by 10% in FY2010
  - Business to Hit Bottom in FY2013
  - New Products to Drive Business in Japan
  - To Focus on Lifestyle-Related Diseases, Cancer, CNS in R&D
- 6 Astellas: Profits Down >25% Due to Patent Expiration for Prograf
  - Business to Hit Bottom in FY2010: Mr Nogimori
  - To Apply for YM150 within 2010 in Japan
- 7 Daiichi Sankyo: Sales Up 13.1% Driven by Olmesartan, Ranbaxy
  - Edoxaban to Be World's 3rd Oral Anti-Xa Agent
- 8 Eisai: Aricept, Cancer-Related Products Drive Sales Up 2.7%
  - Japan to Make Up for Slowdown in the US
  - Eisai to Enhance Global Presence in Oncology with Eribulin
  - New Sales Subsidiary in Canada
- 10 MTPC: Pharma Sales Up 2.2% Driven by Remicade
  - Medway Issues to Be Handled by Office Reporting Directly to President
  - Kuniaki Kaga to Be Promoted to Managing Executive Officer
- 11 DSP: Overseas Subsidiaries Boost Sales
  - Global Development Strategy to Be Decided by Global PMC
  - Non-Approval of STEDESA by FDA Unexpected
- 12 Shionogi: Crestor, US Subsidiary Drive Sales Up 22.4%
  - Irbetan Neck and Neck with Avapro
  - Wholly-Owned Subsidiary to Be Created to Support Research Activities
- 13 Otsuka HD: Sales of Healthcare Business Up 5.6%
- 14 How Will Distribution Practice Be Improved Following Pricing System Reform? - Part 2
- 18 **BUSINESS NEWS IN BRIEF**
  - Janssen, Takeda to Copromote VELCADE in Japan

- Santen Launches Tafluprost in South Korea
- Daiichi Sankyo Voluntarily Recalls Amplit Tablets 25 mg

## GENERIC

- 19 Need for Biosimilars Highlighted at CPhI 2010 Panel Discussion
  - Optimal Pricing System Needs to Be Established for Biosimilars
- 19 **GENERIC NEWS IN BRIEF**
  - Teva-Kowa to Integrate Taisho Pharm's Marketing Division in July
  - Kissei to Launch Japan's 1st EPO Biosimilar
  - Taiyo Yakuin Recalls Another Product
- 20 Major New Entrants in Generics Market, Emergence of AGs

## MEDICAL DEVICES

- 23 3 Medical Devices Recommended for Approval

## REGULATORY

- 24 **REGULATORY NEWS IN BRIEF**
  - GSK's Ofatumumab Receives Conditional Approval in EU
  - New Indication for Actemra Approved in Europe
  - *Koroshio* Calls For Cautions for ILD in Patients Receiving Statins

## R&D

- 25 **R&D NEWS IN BRIEF**
  - GAMMAGARD Improves Cognitive Function in AD Patients in PII: Baxter
  - Gaslon Accelerates Gastric Ulcer Healing after HP Infection
- 25 **TOPICS**
  - Humira Achieves Clinical Remission Rate of 17.7% in 24 Weeks: PMS Data

## MEDICAL FACILITIES & NURSING CARE

- 26 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
  - Equa Can Become 1st-Choice DPP-4 Inhibitor: Prof. Kadowaki
  - Proper Use of Topical Steroids Should Be Promoted: Prof. Horio
  - Erbitux Makes Hepatic Metastasis of Colon Cancer Curable: Prof. Sugihara
  - Cervarix Shows Immunological Responses Significantly Higher Than Gardasil: Dr Einstein
  - Cervarix Offers "Excellent Protection" for Japanese Women As Well: Prof. Konno